

Paul D Bieniasz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3529523/paul-d-bieniasz-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

197 papers	24,095 citations	76 h-index	154 g-index
220 ext. papers	30,174 ext. citations	17.7 avg, IF	7.29 L-index

#	Paper	IF	Citations
197	A diverse range of gene products are effectors of the type I interferon antiviral response. <i>Nature</i> , 2011 , 472, 481-5	50.4	1584
196	Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. <i>Nature</i> , 2008 , 451, 425-30	50.4	1369
195	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020 , 584, 437-442	50.4	1167
194	Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. <i>Nature</i> , 2007 , 446, 801-5	50.4	970
193	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020 , 9,	8.9	784
192	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021 , 592, 616-622	50.4	730
191	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021 , 591, 639-644	50.4	652
190	HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. <i>Nature Medicine</i> , 2001 , 7, 1313-9	50.5	615
189	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020 , 182, 828-842.e16	56.2	485
188	Tetherin inhibits HIV-1 release by directly tethering virions to cells. <i>Cell</i> , 2009 , 139, 499-511	56.2	439
187	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. <i>Nature</i> , 2012 , 492, 118-22	50.4	401
186	Intrinsic immunity: a front-line defense against viral attack. <i>Nature Immunology</i> , 2004 , 5, 1109-15	19.1	357
185	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , 2021 , 384, 2212-2218	59.2	347
184	Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. <i>Cell Host and Microbe</i> , 2009 , 6, 409-21	23.4	339
183	MX2 is an interferon-induced inhibitor of HIV-1 infection. <i>Nature</i> , 2013 , 502, 563-6	50.4	337
182	HIV Restriction Factors and Mechanisms of Evasion. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012 , 2, a006940	5.4	333
181	Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 12414-9	11.5	333

180	Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. <i>Journal of Virology</i> , 2009 , 83, 1837-44	6.6	319
179	Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 10774-9	11.5	315
178	Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. <i>Nature Medicine</i> , 2003 , 9, 1138-43	9.9	313
177	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	289
176	Nef proteins from simian immunodeficiency viruses are tetherin antagonists. <i>Cell Host and Microbe</i> , 2009 , 6, 54-67	23.4	288
175	Plasma membrane is the site of productive HIV-1 particle assembly. <i>PLoS Biology</i> , 2006 , 4, e435	9.7	269
174	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021 , 595, 426-431	50.4	247
173	Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. <i>PLoS Pathogens</i> , 2009 , 5, e1000300	7.6	246
172	Imaging the biogenesis of individual HIV-1 virions in live cells. <i>Nature</i> , 2008 , 454, 236-40	50.4	246
171	Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 11914-9	11.5	242
170	APOBEC3G incorporation into human immunodeficiency virus type 1 particles. <i>Journal of Virology</i> , 2004 , 78, 12058-61	6.6	238
169	Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. <i>EMBO Journal</i> , 1998 , 17, 7056-65	13	232
168	Role of ESCRT-I in retroviral budding. <i>Journal of Virology</i> , 2003 , 77, 4794-804	6.6	219
167	Reconstitution of an infectious human endogenous retrovirus. <i>PLoS Pathogens</i> , 2007 , 3, e10	7.6	214
166	CG dinucleotide suppression enables antiviral defence targeting non-self RNA. <i>Nature</i> , 2017 , 550, 124-127	50.4	211
165	HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. <i>PLoS Pathogens</i> , 2006 , 2, e39	7.6	211
164	Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. <i>PLoS Pathogens</i> , 2005 , 1, e6	7.6	211
163	An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. <i>Cell Host and Microbe</i> , 2007 , 2, 193-203	23.4	208

162	Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. <i>Journal of Virology</i> , 2005 , 79, 8969-78	6.6	207
161	Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 19114-9	11.5	201
160	Restriction of multiple divergent retroviruses by Lv1 and Ref1. <i>EMBO Journal</i> , 2003 , 22, 385-94	13	194
159	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	178
158	Dynamics of ESCRT protein recruitment during retroviral assembly. <i>Nature Cell Biology</i> , 2011 , 13, 394-401	13.4	172
157	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	171
156	HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. <i>Journal of Cell Biology</i> , 2005 , 168, 89-101	7.3	168
155	Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. <i>Journal of Virology</i> , 2000 , 74, 9868-77	6.6	165
154	Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. <i>Journal of Virology</i> , 2005 , 79, 176-83	6.6	164
153	The cell biology of HIV-1 virion genesis. <i>Cell Host and Microbe</i> , 2009 , 5, 550-8	23.4	162
152	Global changes in the RNA binding specificity of HIV-1 gag regulate virion genesis. <i>Cell</i> , 2014 , 159, 1096-1109	16.9	161
151	Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3563-8	11.5	159
150	Analysis of the initiating events in HIV-1 particle assembly and genome packaging. <i>PLoS Pathogens</i> , 2010 , 6, e1001200	7.6	143
149	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. <i>Journal of Infectious Diseases</i> , 2021 , 223, 389-398	7	136
148	Extreme genetic fragility of the HIV-1 capsid. <i>PLoS Pathogens</i> , 2013 , 9, e1003461	7.6	134
147	Identification of Interferon-Stimulated Genes with Antiretroviral Activity. <i>Cell Host and Microbe</i> , 2016 , 20, 392-405	23.4	126
146	Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. <i>Journal of Virology</i> , 2005 , 79, 15567-72	6.6	126
145	A macaque model of HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 4425-9	11.5	124

144	Generation of simian-tropic HIV-1 by restriction factor evasion. <i>Science</i> , 2006 , 314, 95	33.3	123
143	Context-dependent effects of L domains and ubiquitination on viral budding. <i>Journal of Virology</i> , 2004 , 78, 5554-63	6.6	122
142	SAMHD1-dependent retroviral control and escape in mice. <i>EMBO Journal</i> , 2013 , 32, 2454-62	13	116
141	The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. <i>PLoS Pathogens</i> , 2010 , 6, e1000843	7.6	113
140	Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. <i>Journal of Virology</i> , 2004 , 78, 6005-12	6.6	110
139	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	110
138	Host and viral determinants of Mx2 antiretroviral activity. <i>Journal of Virology</i> , 2014 , 88, 7738-52	6.6	107
137	Human immunodeficiency virus, restriction factors, and interferon. <i>Journal of Interferon and Cytokine Research</i> , 2009 , 29, 569-80	3.5	106
136	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021 , 12, 4196	17.4	106
135	Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 18097-101	11.5	103
134	A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. <i>Journal of Cell Biology</i> , 2009 , 184, 881-94	7.3	96
133	Restriction factors: a defense against retroviral infection. <i>Trends in Microbiology</i> , 2003 , 11, 286-91	12.4	94
132	Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. <i>Journal of Virology</i> , 2002 , 76, 6332-43	6.6	94
131	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. <i>New England Journal of Medicine</i> , 2021 ,	59.2	93
130	A serpin shapes the extracellular environment to prevent influenza A virus maturation. <i>Cell</i> , 2015 , 160, 631-643	56.2	90
129	Structural insight into the mechanisms of enveloped virus tethering by tetherin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 18428-32	11.5	87
128	Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. <i>Virology</i> , 2006 , 349, 31-40	3.6	87
127	Intrinsic cellular defenses against human immunodeficiency viruses. <i>Immunity</i> , 2012 , 37, 399-411	32.3	85

126	Vpu binds directly to tetherin and displaces it from nascent virions. <i>PLoS Pathogens</i> , 2013 , 9, e1003299	7.6	83
125	Integration target site selection by a resurrected human endogenous retrovirus. <i>Genes and Development</i> , 2009 , 23, 633-42	12.6	83
124	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021 , 54, 1853-1868.e7	32.3	83
123	Mechanism of HIV-1 virion entrapment by tetherin. <i>PLoS Pathogens</i> , 2013 , 9, e1003483	7.6	79
122	Temporal and spatial organization of ESCRT protein recruitment during HIV-1 budding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 12211-6	11.5	76
121	Hypermutation of an ancient human retrovirus by APOBEC3G. <i>Journal of Virology</i> , 2008 , 82, 8762-70	6.6	76
120	Ubiquitin-dependent virus particle budding without viral protein ubiquitination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 20031-6	11.5	74
119	A comparative study of higher primate foamy viruses, including a new virus from a gorilla. <i>Virology</i> , 1995 , 207, 217-28	3.6	74
118	Fates of retroviral core components during unrestricted and TRIM5-restricted infection. <i>PLoS Pathogens</i> , 2013 , 9, e1003214	7.6	73
117	Human immunodeficiency virus type 1 matrix inhibits and confers cooperativity on gag precursor-membrane interactions. <i>Journal of Virology</i> , 2004 , 78, 9560-3	6.6	73
116	HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis. <i>Cell</i> , 2016 , 166, 1257-1268.e12	56.2	72
115	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021 ,	50.4	69
114	HIV/AIDS: in search of an animal model. <i>Trends in Biotechnology</i> , 2007 , 25, 333-7	15.1	68
113	Structure of the zinc-finger antiviral protein in complex with RNA reveals a mechanism for selective targeting of CG-rich viral sequences. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 24303-24309	11.5	66
112	Identification of human VPS37C, a component of endosomal sorting complex required for transport-I important for viral budding. <i>Journal of Biological Chemistry</i> , 2005 , 280, 628-36	5.4	65
111	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , 2021 ,	50.4	65
110	Visualizing HIV-1 assembly. <i>Journal of Molecular Biology</i> , 2011 , 410, 501-11	6.5	63
109	HIV-1-induced AIDS in monkeys. <i>Science</i> , 2014 , 344, 1401-5	33.3	61

108	Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates. <i>Journal of Virology</i> , 1998 , 72, 1918-24	6.6	60
107	Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. <i>ELife</i> , 2018 , 7,	8.9	59
106	Functional interchangeability of late domains, late domain cofactors and ubiquitin in viral budding. <i>PLoS Pathogens</i> , 2010 , 6, e1001153	7.6	55
105	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants 2021 ,		54
104	SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. <i>PLoS Pathogens</i> , 2011 , 7, e1002039	7.6	52
103	A bipartite late-budding domain in human immunodeficiency virus type 1. <i>Journal of Virology</i> , 2003 , 77, 12373-7	6.6	51
102	Determination of RNA structural diversity and its role in HIV-1 RNA splicing. <i>Nature</i> , 2020 , 582, 438-442	50.4	50
101	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021 , 595, 278-282	50.4	49
100	Single-Cell and Single-Cycle Analysis of HIV-1 Replication. <i>PLoS Pathogens</i> , 2015 , 11, e1004961	7.6	48
99	No evidence of antibody to human foamy virus in widespread human populations. <i>AIDS Research and Human Retroviruses</i> , 1996 , 12, 1473-83	1.6	48
98	Inhibition of HIV-1 particle assembly by 2T3Tcyclic-nucleotide 3Tphosphodiesterase. <i>Cell Host and Microbe</i> , 2012 , 12, 585-97	23.4	45
97	Primate lentivirus capsid sensitivity to TRIM5 proteins. <i>Journal of Virology</i> , 2008 , 82, 6772-7	6.6	45
96	Sequences in pol are required for transfer of human foamy virus-based vectors. <i>Journal of Virology</i> , 1998 , 72, 5510-6	6.6	44
95	Co-option of an endogenous retrovirus envelope for host defense in hominid ancestors. <i>ELife</i> , 2017 , 6,	8.9	43
94	Evolution of Antibody Immunity to SARS-CoV-2 2021 ,		43
93	Clathrin facilitates the morphogenesis of retrovirus particles. <i>PLoS Pathogens</i> , 2011 , 7, e1002119	7.6	42
92	Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. <i>Cell Host and Microbe</i> , 2014 , 16, 412-8	23.4	41
91	Tetherin promotes the innate and adaptive cell-mediated immune response against retrovirus infection in vivo. <i>Journal of Immunology</i> , 2014 , 193, 306-16	5.3	40

90	Capsid-dependent and -independent postentry restriction of primate lentivirus tropism in rodent cells. <i>Journal of Virology</i> , 2004 , 78, 1006-11	6.6	39
89	Identification of domains in gag important for prototypic foamy virus egress. <i>Journal of Virology</i> , 2005 , 79, 6392-9	6.6	38
88	Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. <i>Molecular and Cellular Biology</i> , 1999 , 19, 4592-9	4.8	38
87	Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents 2020 ,		37
86	Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1208-e1211	11.6	37
85	Analysis of the human immunodeficiency virus-1 RNA packageome. <i>Rna</i> , 2016 , 22, 1228-38	5.8	36
84	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. <i>Nature</i> , 2021 , 593, 424-428	50.4	36
83	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses 2020 ,		35
82	The RNA Binding Specificity of Human APOBEC3 Proteins Resembles That of HIV-1 Nucleocapsid. <i>PLoS Pathogens</i> , 2016 , 12, e1005833	7.6	35
81	Multiple, Switchable Protein:RNA Interactions Regulate Human Immunodeficiency Virus Type 1 Assembly. <i>Annual Review of Virology</i> , 2018 , 5, 165-183	14.6	33
80	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants 2020 ,		32
79	No effect of endogenous TRIM5alpha on HIV-1 production. <i>Nature Medicine</i> , 2008 , 14, 235-6; author reply 236-8	50.5	31
78	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. 2021 ,		31
77	Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants 2020 ,		31
76	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021 , 184, 3205-3221.e24	32.1	31
75	Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes. <i>Journal of Virology</i> , 1999 , 73, 5777-86	6.6	30
74	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies 2020 ,		30
73	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients 2020 ,		30

72	Evidence for restriction of ancient primate gammaretroviruses by APOBEC3 but not TRIM5alpha proteins. <i>PLoS Pathogens</i> , 2008 , 4, e1000181	7.6	29
71	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , 2021 , 36, 109760	10.6	29
70	Antiretroviral restriction factors. <i>Current Opinion in Virology</i> , 2011 , 1, 526-32	7.5	28
69	Effect of DNA repair protein Rad18 on viral infection. <i>PLoS Pathogens</i> , 2006 , 2, e40	7.6	28
68	The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles. <i>Journal of Virology</i> , 2006 , 80, 12102-8	6.6	28
67	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies 2021 ,		27
66	Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses. <i>Journal of Virology</i> , 2013 , 87, 3549-60	6.6	26
65	Global synonymous mutagenesis identifies cis-acting RNA elements that regulate HIV-1 splicing and replication. <i>PLoS Pathogens</i> , 2018 , 14, e1006824	7.6	26
64	Assisted evolution enables HIV-1 to overcome a high TRIM5 α -imposed genetic barrier to rhesus macaque tropism. <i>PLoS Pathogens</i> , 2013 , 9, e1003667	7.6	24
63	HIV-1 at 25. <i>Cell</i> , 2008 , 133, 561-5	56.2	24
62	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies 2021 ,		24
61	Matrix-induced inhibition of membrane binding contributes to human immunodeficiency virus type 1 particle assembly defects in murine cells. <i>Journal of Virology</i> , 2005 , 79, 15586-9	6.6	23
60	Role of chemokine receptors in HIV-1 infection and pathogenesis. <i>Advances in Virus Research</i> , 1999 , 52, 233-67	10.7	22
59	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection 2020 ,		21
58	A single gp120 residue can affect HIV-1 tropism in macaques. <i>PLoS Pathogens</i> , 2017 , 13, e1006572	7.6	20
57	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year 2021 ,		19
56	Uneven genetic robustness of HIV-1 integrase. <i>Journal of Virology</i> , 2015 , 89, 552-67	6.6	18
55	Origins and Evolution of tetherin, an Orphan Antiviral Gene. <i>Cell Host and Microbe</i> , 2016 , 20, 189-201	23.4	17

54	Identification of a receptor for an extinct virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 19496-501	11.5	17
53	Cyclin T1 expression is mediated by a complex and constitutively active promoter and does not limit human immunodeficiency virus type 1 Tat function in unstimulated primary lymphocytes. <i>Journal of Virology</i> , 2002 , 76, 208-19	6.6	16
52	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. <i>Cell Host and Microbe</i> , 2020 , 27, 963-975.e5	23.4	16
51	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro 2020 ,		15
50	An overview of intracellular interactions between immunodeficiency viruses and their hosts. <i>Aids</i> , 2012 , 26, 1243-54	3.5	14
49	The aryl hydrocarbon receptor and interferon gamma generate antiviral states via transcriptional repression. <i>ELife</i> , 2018 , 7,	8.9	14
48	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. <i>Cell Reports Medicine</i> , 2021 , 2, 100164	18	14
47	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. <i>Nature</i> , 2022 ,	50.4	14
46	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies 2021 ,		13
45	Vesicular Stomatitis Virus Transcription Is Inhibited by TRIM69 in the Interferon-Induced Antiviral State. <i>Journal of Virology</i> , 2019 , 93,	6.6	13
44	Tetherin Inhibits Cell-Free Virus Dissemination and Retards Murine Leukemia Virus Pathogenesis. <i>Journal of Virology</i> , 2017 , 91,	6.6	12
43	HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. <i>ELife</i> , 2020 , 9,	8.9	12
42	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. <i>Nature Immunology</i> , 2021 , 22, 1503-1514	19.1	12
41	Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection 2020 ,		12
40	Genome-Wide Analysis of Heterogeneous Nuclear Ribonucleoprotein (hnRNP) Binding to HIV-1 RNA Reveals a Key Role for hnRNP H1 in Alternative Viral mRNA Splicing. <i>Journal of Virology</i> , 2019 , 93,	6.6	11
39	Predictors of Nonseroconversion after SARS-CoV-2 Infection. <i>Emerging Infectious Diseases</i> , 2021 , 27, 2454-2458	10.2	11
38	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. <i>Immunity</i> , 2022 ,	32.3	10
37	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , 2019 , 15, e1007632	7.6	9

36	CLIP-related methodologies and their application to retrovirology. <i>Retrovirology</i> , 2018 , 15, 35	3.6	8
35	An intrinsic host defense against HIV-1 integration?. <i>Journal of Clinical Investigation</i> , 2007 , 117, 302-4	15.9	8
34	Multimeric nanobodies from camelid engineered mice and llamas potentially neutralize SARS-CoV-2 variants 2021 ,		8
33	Replication and single-cycle delivery of SARS-CoV-2 replicons. <i>Science</i> , 2021 , 374, 1099-1106	33.3	7
32	Inhibition of spumavirus gene expression by PHF11. <i>PLoS Pathogens</i> , 2020 , 16, e1008644	7.6	7
31	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
30	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , 2021 , 17, e1009688	7.6	7
29	Mechanisms of Attenuation by Genetic Recoding of Viruses. <i>MBio</i> , 2021 , 12,	7.8	7
28	High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies		7
27	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 10504-10509	11.5	6
26	Reconstruction of a replication-competent ancestral murine endogenous retrovirus-L. <i>Retrovirology</i> , 2018 , 15, 34	3.6	6
25	Origin and evolution of the zinc finger antiviral protein. <i>PLoS Pathogens</i> , 2021 , 17, e1009545	7.6	6
24	HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. <i>Cell Host and Microbe</i> , 2021 , 29, 1421-1436.e7	23.4	5
23	Development of a rapid quantitative assay for HIV-1 plasma infectious viraemia-culture-PCR (CPID). <i>Journal of Medical Virology</i> , 1994 , 43, 28-32	19.7	4
22	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. <i>ELife</i> , 2019 , 8,	8.9	4
21	Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2 2021 ,		4
20	Repurposing a Bacterial Immune System to Discover Antiviral Targets. <i>New England Journal of Medicine</i> , 2017 , 376, 1290-1291	59.2	3
19	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , 2021 , 10,	8.9	3

18	Functional Differences between Human and Bovine Immunodeficiency Virus Tat Transcription Factors. <i>Journal of Virology</i> , 2000 , 74, 4666-4671	6.6	3
17	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. 2022 ,		3
16	VPS29 Exerts Opposing Effects on Endocytic Viral Entry.. <i>MBio</i> , 2022 , e0300221	7.8	3
15	Sensing retroviruses. <i>Immunity</i> , 2011 , 35, 8-10	32.3	2
14	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity 2021 ,		2
13	Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease 2021 ,		2
12	Derivation and characterization of an HIV-1 mutant that rescues IP binding deficiency. <i>Retrovirology</i> , 2021 , 18, 25	3.6	2
11	A multimodal antiretroviral protein. <i>Nature Microbiology</i> , 2018 , 3, 122-123	26.6	1
10	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. 2022 ,		1
9	Poly(ADP-ribose) potentiates ZAP antiviral activity.. <i>PLoS Pathogens</i> , 2022 , 18, e1009202	7.6	1
8	Origin and evolution of the Zinc Finger Antiviral Protein		1
7	Poly(ADP-ribose) potentiates ZAP antiviral activity		1
6	A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques 2020 ,		1
5	Vesicular stomatitis virus transcription is inhibited by TRIM69 in the interferon-induced antiviral state		1
4	A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques 2021 ,		1
3	Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting.. <i>PLoS ONE</i> , 2022 , 17, e0266086	3.7	0
2	Short Communication: Ultrasensitive Immunoassay for Assessing Residual Simian-Tropic HIV in Nonhuman Primate Models of AIDS. <i>AIDS Research and Human Retroviruses</i> , 2019 , 35, 473-476	1.6	
1	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland.. <i>Journal of Clinical Virology Plus</i> , 2021 , 1, 100028		

